Literature DB >> 20660055

High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.

Silviu Sbiera1, Sebastian Schmull, Guillaume Assie, Hans-Ullrich Voelker, Luitgard Kraus, Melanie Beyer, Bruno Ragazzon, Felix Beuschlein, Holger S Willenberg, Stefanie Hahner, Wolfgang Saeger, Jerome Bertherat, Bruno Allolio, Martin Fassnacht.   

Abstract

CONTEXT: No immunohistochemical marker has been established to reliably differentiate adrenocortical tumors from other adrenal masses. A panel of markers like melan-A and inhibin-α is currently used for this purpose but suffers from limited diagnostic accuracy. We hypothesized that expression of steroidogenic factor-1 (SF-1), a transcription factor involved in adrenal development, is of value for the differential diagnosis of adrenal masses and predicts prognosis in adrenocortical carcinoma (ACC). PATIENTS AND METHODS: SF-1 protein expression was assessed by immunohistochemistry on tissue samples from 167 ACC, 52 adrenocortical adenomas (ACA), six normal adrenal glands, six normal ovaries and 73 neoplastic nonsteroidogenic tissues. In an independent cohort of 33 ACC and 58 ACA, SF-1 mRNA expression was analyzed. SF-1 expression was correlated with clinical outcome in patients with ACC.
RESULTS: SF-1 protein staining was detectable in 158 of 161 (98%) evaluable ACC samples including 49 (30%) with strong SF-1 staining and in all normal and benign steroidogenic tissues. In addition, SF-1 mRNA expression was present in all 91 analyzed adrenocortical tumors. In contrast, SF-1 expression was absent in all nonsteroidogenic tumors. Strong SF-1 protein expression significantly correlated with poor clinical outcome: tumor stage-adjusted hazard ratio for death 2.46 [95% confidence interval (CI) = 1.30-4.64] and for recurrence 3.91 (95% CI = 1.71-8.94). Similar results were obtained in the independent cohort using RNA analysis [tumor stage-adjusted hazard ratio for death 4.69 (95% CI = 1.44-15.30)].
CONCLUSION: SF-1 is a highly valuable immunohistochemical marker to determine the adrenocortical origin of an adrenal mass with high sensitivity and specificity. In addition, SF-1 expression is of stage-independent prognostic value in patients with ACC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660055     DOI: 10.1210/jc.2010-0653

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  64 in total

Review 1.  Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?

Authors:  E Baudin; S Leboulleux; A Al Ghuzlan; C Chougnet; J Young; D Deandreis; F Dumont; F Dechamps; C Caramella; P Chanson; E Lanoy; I Borget; M Schlumberger
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

Review 2.  Adrenocortical stem and progenitor cells: implications for adrenocortical carcinoma.

Authors:  Derek P Simon; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2012-01-13       Impact factor: 4.102

3.  Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.

Authors:  Matthias Kroiss; Silviu Sbiera; Sabine Kendl; Max Kurlbaum; Martin Fassnacht
Journal:  Horm Cancer       Date:  2016-09-08       Impact factor: 3.869

4.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

5.  Emerging therapy for adrenocortical carcinoma.

Authors:  Rachel D Aufforth; Naris Nilubol
Journal:  Int J Endocr Oncol       Date:  2014

6.  Gaining traction in the treatment of adrenocortical carcinoma.

Authors:  Lawrence S Kirschner
Journal:  J Clin Endocrinol Metab       Date:  2013-01       Impact factor: 5.958

Review 7.  Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma.

Authors:  Hironobu Sasano; Fumitoshi Satoh; Yasuhiro Nakamura
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

8.  FATE1 antagonizes calcium- and drug-induced apoptosis by uncoupling ER and mitochondria.

Authors:  Mabrouka Doghman-Bouguerra; Veronica Granatiero; Silviu Sbiera; Iuliu Sbiera; Sandra Lacas-Gervais; Frédéric Brau; Martin Fassnacht; Rosario Rizzuto; Enzo Lalli
Journal:  EMBO Rep       Date:  2016-07-11       Impact factor: 8.807

Review 9.  Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms.

Authors:  Ozgur Mete; Sylvia L Asa; Thomas J Giordano; Mauro Papotti; Hironobu Sasano; Marco Volante
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

10.  SF-1 deficiency causes lipid accumulation in Leydig cells via suppression of STAR and CYP11A1.

Authors:  Megumi Hatano; Toshiro Migita; Tomokazu Ohishi; Yuichi Shima; Yoshihiro Ogawa; Ken-Ichirou Morohashi; Yukihiro Hasegawa; Futoshi Shibasaki
Journal:  Endocrine       Date:  2016-07-25       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.